«This is an encouraging first step in
Zika vaccine design and pre-clinical testing.
Not exact matches
Now that boost in
Zika - linked Guillain (GBS) is stoking concerns that a
vaccine designed to protect patients against
Zika could inadvertently provoke more cases of the autoimmune condition.
«The emergence of
Zika virus has further complicated
vaccine design, and emphasizes the need to better understand the molecular mechanisms that underpin protective antibody responses.»
«Having the structure of the full - length
Zika NS1 provides new information that can help guide the
design of a potential
vaccine or antiviral drugs,» said senior author Janet Smith, director of the Center for Structural Biology at the U-M Life Sciences Institute, where her lab is located, and professor of biological chemistry at the U-M Medical School.
Ferguson's team is calling for trials of
Zika treatments and
vaccines to be
designed so that even if the epidemic burns out, they are ready to kick in quickly should
Zika roar back again.
This is a very exciting discovery as it offers numerous possibilities of
designing therapies and
vaccines to target these exposed surfaces to treat dengue as well as other related viruses such as
Zika and chikungunya.
In just the last 6 years the EID outbreaks of MERS, Ebola,
Zika, CHIKV as examples have underscored the importance of rapid
vaccine development and deployment capabilities to meet EID challenges, as well as growing appreciation for creativity and flexibility in clinical trial
design.
«This is a straightforward study of the use of two established
vaccine technologies in an attempt to
design and test new
Zika vaccines.
Using enhanced DNA technology, the lab has
designed DNA
vaccines that drive immune responses in prophylactic or therapeutic settings against Human Immunodeficiency Virus (HIV), Dengue (DV), Chikungunya virus (CHIKV), Middle Eastern Respiratory Syndrome (MERS) virus, and
Zika Virus (ZV).